IVD 수탁 제조 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 제품별, 서비스별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

In Vitro Diagnostics Contract Manufacturing Market Growth & Trends:

The global in vitro diagnostics contract manufacturing market size is expected to reach USD 37.45 billion by 2030, registering a CAGR of 10.4% from 2025 to 2030, according to a new report by Grand View Research, Inc.

The market is anticipated to witness lucrative growth potential owing to rising demand for diagnostic devices, an upsurge in point-of-care diagnostics, advancements in molecular testing, and the increasing prevalence of chronic diseases. Moreover, the growing need for cost-effective manufacturing, technological innovation, and stringent regulatory compliance for diagnostics is expected to drive the market revenue stream. Thus, the increasing trend for outsourcing manufacturing services to CMOs and CDMOs to access specialized expertise, streamline production, and accelerate time-to-market among healthcare companies is boosting overall market growth.

The high cost of in-house IVD manufacturing is a significant driver propelling the market growth. The need for high capital investment in infrastructure, specialized equipment, regulatory compliance, and skilled workforce to develop and scale up IVD production will accelerate market growth. These overhead costs strain resources, reducing profitability and flexibility among several small and medium-scale organizations. Thus, by outsourcing manufacturing services to CMOs & CDMOs, companies can lower manufacturing costs and gain access to innovative technologies exclusive of the need for internal capital investment. Moreover, outsourcing allows faster market entry, enhanced scalability, and better resource optimization and offers a competitive edge in the IVD market.

Furthermore, continuous technological advancements are among the major factors accelerating the market demand, specifically for diagnostic devices and testing solutions. Innovations such as molecular diagnostics, next-generation sequencing (NGS), and automation have enhanced the accuracy, speed, and efficiency of IVD manufacturing processes. These advancements assist manufacturers to meet the increasing demand for personalized medicine, point-of-care diagnostics, and faster disease detection methods. Moreover, the integration of AI-driven technologies and data analytics optimizes production workflows and quality assurance processes, enhancing precision and compliance with regulatory standards. Furthermore, numerous healthcare companies are involved in collaboration with contract manufacturers to access such novel technologies to accelerate time-to-market, reduce operational costs, and enhance product scalability. Thus, the integration of advanced technologies by service providers is estimated to drive market growth in the forthcoming years.

In Vitro Diagnostics Contract Manufacturing Market Report Highlights:

• Based on product, the market includes instruments, reagents & consumables, software & services. In 2024, the reagents & consumables segment accounted for the largest revenue share of 69.41%.
• Based on service, the market is segmented into manufacturing services, assay development services, and other services. The manufacturing services segment accounted for the largest market share in 2024.
• Based on technology, the market is segmented into immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation, and others. The immunoassays segment dominated the market with the largest revenue share in 2024.
• In terms of end use, the market is segmented into medical device companies, academic & research institutions, and others. The medical device companies segment dominated the market with the largest revenue share in 2024.
• North America in vitro diagnostics contract manufacturing market dominated the global market in 2024 with the largest share of 41.83%. The in vitro diagnostics contract manufacturing market in Asia Pacific is expected to witness the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates And Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. In Vitro Diagnostics (IVD) Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Industry Ecosystem Analysis
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. In Vitro Diagnostics (IVD) Contract Manufacturing Market: Phases Estimates & Trend Analysis

• 4.1. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By Product: Segment Dashboard
• 4.2. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By Product: Movement Analysis
• 4.3. In Vitro Diagnostics (IVD) Contract Manufacturing Market Estimates & Forecasts, By Product, 2018 - 2030 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Reagents & Consumables
  • 4.5.1. Reagents & Consumables Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Software & Services
  • 4.6.1. Software & Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. In Vitro Diagnostics (IVD) Contract Manufacturing Market: Service Estimates & Trend Analysis

• 5.1. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By Service: Segment Dashboard
• 5.2. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By Service: Movement Analysis
• 5.3. In Vitro Diagnostics (IVD) Contract Manufacturing Market Estimates & Forecasts, By Service, 2018 - 2030 (USD Million)
• 5.4. Manufacturing Services
  • 5.4.1. Manufacturing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Assay Development Services
  • 5.5.1. Assay Development Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Other Services
  • 5.6.1. Other Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. In Vitro Diagnostics (IVD) Contract Manufacturing Market: Technology Estimates & Trend Analysis

• 6.1. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By Technology: Segment Dashboard
• 6.2. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By Technology: Movement Analysis
• 6.3. In Vitro Diagnostics (IVD) Contract Manufacturing Market Estimates & Forecasts, By Technology, 2018 - 2030
• 6.4. Immunoassays
  • 6.4.1. Immunoassays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Clinical Chemistry
  • 6.5.1. Clinical Chemistry Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Molecular Diagnostics
  • 6.6.1. Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Hematology
  • 6.7.1. Hematology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Microbiology
  • 6.8.1. Microbiology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.9. Coagulation
  • 6.9.1. Coagulation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.10. Others
  • 6.10.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. In Vitro Diagnostics (IVD) Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 7.1. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By End Use: Segment Dashboard
• 7.2. In Vitro Diagnostics (IVD) Contract Manufacturing Market, By End Use: Movement Analysis
• 7.3. In Vitro Diagnostics (IVD) Contract Manufacturing Market Estimates & Forecasts, By End Use, 2018 - 2030 (USD Million)
• 7.4. Medical Device Companies
  • 7.4.1. Medical Device Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Academic & Research Institutions
  • 7.5.1. Academic & Research Institutions Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. In Vitro Diagnostics (IVD) Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. North America
  • 8.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Sweden
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Thailand
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Australia
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Service Heat Map Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. Jabil Inc.
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Sanmina Corporation
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. TE Connectivity
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Celestica Inc.
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Savyon Diagnostics
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. West Pharmaceutical Services, Inc.
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Thermo Fisher Scientific
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. KMC Systems
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Cenogenics Corporation
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Novo Biomedical
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Cone Bioproducts
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Invetech
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. AVIOQ Inc.
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. Meridian Bioscience Inc.
    • 9.3.14.1. Company Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Service Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. Nemera
    • 9.3.15.1. Company Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Service Benchmarking
    • 9.3.15.4. Strategic Initiatives